Effects of nitrendipine and enalapril on left ventricular mass in patients with non‐insulin‐dependent diabetes mellitus and hypertension

Tanneke A. Gerritsen,A. Bak,R. Stolk,J. Jonker,D. Grobbee
DOI: https://doi.org/10.1097/00004872-199816050-00017
IF: 4.9
1998-05-01
Journal of Hypertension
Abstract:Objective To compare the effects of a calcium antagonist (nitrendipine) and an angiotensin converting enzyme inhibitor (enalapril) with those of placebo on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension. Design A double-blind randomized, placebo-controlled trial. Setting General practitioners referred patients to the trial physician. Patients The study population comprised 121 patients with non-insulin-dependent diabetes mellitus. Inclusion criteria for blood pressure were diastolic blood pressure 90–115 mmHg and systolic blood pressure ⩽ 200 mmHg, while subjects were not being administered blood-pressure-lowering drugs for 3 weeks. Intervention Patients were randomly allocated to receive nitrendipine (n = 40), enalapril (n = 40) or placebo (n = 41). The treatment period was 48 weeks. Main outcome measures The effect of nitrendipine was defined as the difference in change in left ventricular mass index from baseline between nitrendipine treatment and placebo after 48 weeks of treatment. The effects of nitrendipine compared with that of enalapril and of enalapril compared with placebo were defined similarly. Left ventricular mass was measured by M-mode echocardiography. Results Use of nitrendipine and enalapril led to significant and almost identical reductions in systolic and diastolic blood pressures. During 48 weeks left ventricular mass index decreased by 5% for patients in the nitrendipine group (decrease by 12 g/m2, 95% confidence interval 1–23), remained about the same for patients in the enalapril group (decrease by 1 g/m2, 95% confidence interval decrease by 10 to increase by 9) and increased by 9% for patients in the placebo group (increase by 9 g/m2, 95% confidence interval 2–16). Conclusion These results indicate that administration of nitrendipine to patients with non-insulin-dependent diabetes mellitus and hypertension reduces left ventricular mass index. Enalapril appears not to induce regression, but perhaps prevents progression with an effect that is intermediate between those of nitrendipine and placebo. J Hypertens 16:689–696 © 1998 Lippincott-Raven Publishers.
What problem does this paper attempt to address?